**Amendments to the Claims:**

This listing of claims will replace all prior versions and listings of claims in the application:

**Listing of Claims:**

1. (Previously presented) A compound of formula (I),




(I)

its stereoisomers and mixtures thereof, its polymorphs and mixtures thereof, and the pharmaceutically acceptable solvates and addition salts of all of them, wherein the central benzene ring may be substituted in *meta*- or *para*- position and,

-A is a radical selected from the group consisting of -OR1, -NR2OR1 and -NR2R3; wherein R1, R2 and R3 independently represent -H or -($C_1$-$C_4$)-alkyl;

-W- is a biradical selected from the group: -NH-CH(E)-, and -N(D)-$CH_2$-$CH_2$-; wherein E is a radical of the -G-I-J-K type and D is a radical of the -G-I'-J-K type where:

-G- is a bond or a -$(CH_2)_{1-4}$- biradical;

-I- is a biradical of a cycle selected from the following groups:

a) cyclopropane, cyclobutane, cyclopentane, cyclohexane and cyclohexene, all optionally substituted by one or several radicals independently selected from -OH, oxo (=O), -CHO, -SH, -$NO_2$, -CN, -F, -Cl, -Br, ($C_1$-$C_4$)-alkanoyl, ($C_1$-$C_4$)-alkoxycarbonyl,

($C_1$-$C_4$)-alkanoyloxy, ($C_1$-$C_4$)-alkylsulphinyl, ($C_1$-$C_4$)-alkylsulphenyl, ($C_1$-$C_4$)-alkylsulphonyl, ($C_1$-$C_4$)-alkyloxy-$SO_2$-, ($C_1$-$C_4$)-alkyl-$SO_2O$-, -NR2R3, -CONR2R3, ($C_1$-$C_4$)-alkyl optionally substituted by one or several -OH or -F, and ($C_1$-$C_4$)-alkoxyl optionally substituted by one or several -OH or -F;

b) a five- or six-membered aromatic heterocycle containing from one to three heteroatoms selected from O, S and N, this heterocycle being optionally substituted by one or several radicals independently selected from -OH, oxo (=O), -CHO, -SH, -$NO_2$, -CN, -F, -Cl, -Br, ($C_1$-$C_4$)-alkanoyl, ($C_1$-$C_4$)-alkoxycarbonyl, ($C_1$-$C_4$)-alkanoyloxy, ($C_1$-$C_4$)-alkylsulphinyl, ($C_1$-$C_4$)-alkylsulphenyl, ($C_1$-$C_4$)-alkylsulphonyl, ($C_1$-$C_4$)-alkyloxy-$SO_2$-, ($C_1$-$C_4$)-alkyl-$SO_2O$-, -NR2R3, -CONR2R3, ($C_1$-$C_4$)-alkyl optionally substituted by one or several -OH or -F, and ($C_1$-$C_4$)-alkoxyl optionally substituted by one or several -OH or -F;

c) benzene or benzene substituted by one or several radicals independently selected from -OH, -CHO, -SH, -$NO_2$, -CN, -F, -Cl, -Br, ($C_1$-$C_4$)-alkanoyl, ($C_1$-$C_4$)-alkoxycarbonyl, ($C_1$-$C_4$)-alkanoyloxy, ($C_1$-$C_4$)-alkylsulphinyl, ($C_1$-$C_4$)-alkylsulphenyl, ($C_1$-$C_4$)-alkylsulphonyl, ($C_1$-$C_4$)-alkyloxy-$SO_2$-, ($C_1$-$C_4$)-alkyl-$SO_2O$-, -NR2R3, -CONR2R3, ($C_1$-$C_4$)-alkyl optionally substituted by one or several -OH or -F, and ($C_1$-$C_4$)-alkoxyl optionally substituted by one or several -OH or -F; and

d) a bicyclic system consisting of a benzene fused with a five- or six-membered ring optionally containing from one to three heteroatoms selected from O, S and N, this bicyclic system being optionally substituted by one or several radicals independently selected from -OH, oxo (=O), -CHO, -SH, -$NO_2$, -CN, -F, -Cl, -Br, ($C_1$-$C_4$)-alkanoyl, ($C_1$-$C_4$)-alkoxycarbonyl,

($C_1$-$C_4$)-alkanoyloxy, ($C_1$-$C_4$)-alkylsulphinyl, ($C_1$-$C_4$)-alkylsulphenyl, ($C_1$-$C_4$)-alkylsulphonyl, ($C_1$-$C_4$)-alkyloxy-$SO_2$-, ($C_1$-$C_4$)-alkyl-$SO_2O$-, -NR2R3, -CONR2R3, ($C_1$-$C_4$)-alkyl optionally substituted by one or several -OH or -F, and ($C_1$-$C_4$)-alkoxyl optionally substituted by one or several -OH or -F;

-J- is a bond or a biradical selected from the following groups:

a) -$(CH_2)_{1-4}$-alkylidene;

b) -O-, and

c) -O-($C_1$-$C_4$)-alkyl;

-K is a radical selected from the following groups:

a) -H;

b) ($C_1$-$C_4$)-alkyl;

c) a radical from a cycle selected from the following: cyclopropane, cyclobutane, cyclopentane, cyclohexane and cyclohexene, all of them optionally substituted by one or several radicals independently selected from -OH, oxo (=O), -CHO, -SH, -$NO_2$, -CN, -F, -Cl, -Br, ($C_1$-$C_4$)-alkanoyl, ($C_1$-$C_4$)-alkoxycarbonyl, ($C_1$-$C_4$)-alkanoyloxy, ($C_1$-$C_4$)-alkylsulphinyl, ($C_1$-$C_4$)-alkylsulphenyl, ($C_1$-$C_4$)-alkylsulphonyl, ($C_1$-$C_4$)-alkyloxy-$SO_2$-, ($C_1$-$C_4$)-alkyl-$SO_2O$-, -NR2R3, -CONR2R3, ($C_1$-$C_4$)-alkyl optionally substituted by one or several -OH or -F, and ($C_1$-$C_4$)-alkoxyl optionally substituted by one or several -OH or -F;

d) a radical from a five- or six-membered heterocycle containing from one to three heteroatoms selected from O, S and N, being this heterocycle optionally substituted by one or several radicals independently selected from -OH, oxo (=O), -CHO, -SH, -$NO_2$, -CN, -F, -Cl, -Br, ($C_1$-$C_4$)-alkanoyl, ($C_1$-$C_4$)-alkoxycarbonyl, ($C_1$-$C_4$)-alkanoyloxy, ($C_1$-$C_4$)-alkylsulphinyl, ($C_1$-$C_4$)-alkylsulphenyl, ($C_1$-$C_4$)-alkylsulphonyl, ($C_1$-$C_4$)-alkyloxy-$SO_2$-, ($C_1$-$C_4$)-alkyl-$SO_2O$-, -NR2R3,

-CONR2R3, ($C_1$-$C_4$)-alkyl optionally substituted by one or several -OH or -F, and ($C_1$-$C_4$)-alkoxyl optionally substituted by one or several -OH or -F; and

e) phenyl or phenyl optionally substituted by one or several radicals independently selected from -OH, -CHO, -SH, -$NO_2$, -CN, -F, -Cl, -Br, ($C_1$-$C_4$)-alkanoyl, ($C_1$-$C_4$)-alkoxycarbonyl, ($C_1$-$C_4$)-alkanoyloxy, ($C_1$-$C_4$)-alkylsulphinyl, ($C_1$-$C_4$)-alkylsulphenyl, ($C_1$-$C_4$)-alkylsulphonyl, ($C_1$-$C_4$)-alkyloxy-$SO_2$-, ($C_1$-$C_4$)-alkyl-$SO_2O$-, -NR2R3, -CONR2R3, ($C_1$-$C_4$)-alkyl optionally substituted by one or several -OH or -F, and ($C_1$-$C_4$)-alkoxyl optionally substituted by one or several -OH or -F;

-I'- is a biradical of a cycle selected from the following groups:

a) cyclopropane, cyclobutane, cyclopentane, cyclohexane and cyclohexene, all optionally substituted by one or several radicals independently selected from -OH, oxo (=O), -CHO, -SH, -$NO_2$, -CN, -F, -Cl, -Br, ($C_1$-$C_4$)-alkanoyl, ($C_1$-$C_4$)-alkoxycarbonyl, ($C_1$-$C_4$)-alkanoyloxy, ($C_1$-$C_4$)-alkylsulphinyl, ($C_1$-$C_4$)-alkylsulphenyl, ($C_1$-$C_4$)-alkylsulphonyl, ($C_1$-$C_4$)-alkyloxy-$SO_2$-, ($C_1$-$C_4$)-alkyl-$SO_2O$-, -NR2R3, -CONR2R3, ($C_1$-$C_4$)-alkyl optionally substituted by one or several -OH or -F, and ($C_1$-$C_4$)-alkoxyl optionally substituted by one or several -OH or -F;

b) a five- or six-membered aromatic heterocycle containing from one to three heteroatoms selected from O, S and N, being this heterocycle optionally substituted by one or several radicals independently selected from -OH, oxo (=O), -CHO, -SH, -$NO_2$, -CN, -F, -Cl, -Br, ($C_1$-$C_4$)-alkanoyl, ($C_1$-$C_4$)-alkoxycarbonyl, ($C_1$-$C_4$)-alkanoyloxy, ($C_1$-$C_4$)-alkylsulphinyl, ($C_1$-$C_4$)-alkylsulphenyl, ($C_1$-$C_4$)-alkylsulphonyl, ($C_1$-$C_4$)-alkyloxy-$SO_2$-, ($C_1$-$C_4$)-alkyl-$SO_2O$-, -NR2R3, -CONR2R3, ($C_1$-$C_4$)-alkyl optionally substituted by one or

several -OH or -F, and ($C_1$-$C_4$)-alkoxyl optionally substituted by one or several -OH or -F;

c) benzene substituted by one or several radicals independently selected from -OH, -CHO, -SH, -$NO_2$, -CN, -F, -Cl, -Br, ($C_1$-$C_4$)-alkanoyl, ($C_1$-$C_4$)-alkoxycarbonyl, ($C_1$-$C_4$)-alkanoyloxy, ($C_1$-$C_4$)-alkylsulphinyl, ($C_1$-$C_4$)-alkylsulphenyl, ($C_1$-$C_4$)-alkylsulphonyl, ($C_1$-$C_4$)-alkyloxy-$SO_2$-, ($C_1$-$C_4$)-alkyl-$SO_2O$-, -NR2R3, -CONR2R3, ($C_1$-$C_4$)-alkyl optionally substituted by one or several -OH or -F, and ($C_1$-$C_4$)-alkoxyl optionally substituted by one or several -OH or -F; and

d) a bicyclic system consisting of a benzene fused with a five- or six-membered ring optionally containing from one to three heteroatoms selected from O, S and N, being this bicyclic system optionally substituted by one or several radicals independently selected from -OH, oxo (=O), -CHO, -SH, -$NO_2$, -CN, -F, -Cl, -Br, ($C_1$-$C_4$)-alkanoyl, ($C_1$-$C_4$)-alkoxycarbonyl, ($C_1$-$C_4$)-alkanoyloxy, ($C_1$-$C_4$)-alkylsulphinyl, ($C_1$-$C_4$)-alkylsulphenyl, ($C_1$-$C_4$)-alkylsulphonyl, ($C_1$-$C_4$)-alkyloxy-$SO_2$-, ($C_1$-$C_4$)-alkyl-$SO_2O$-, -NR2R3, -CONR2R3, ($C_1$-$C_4$)-alkyl optionally substituted by one or several -OH or -F, ($C_1$-$C_4$)-alkoxyl optionally substituted by one or several -OH or -F,phenyl, phenoxy and benzyloxy;

-Z is a radical selected from the following groups:

a) -Q-I-J-T wherein

-Q- is a biradical -($CH_2$)$_{1-3}$-;

-I- is as defined above;

-J- is as defined above; and

-T is a radical selected from the following groups:

a.a) -H;

a.b) ($C_1$-$C_4$)-alkyl;

a.c) a radical from a cycle selected from the following: cyclopropane, cyclobutane, cyclopentane, cyclohexane and cyclohexene, all of them optionally substituted by one or several radicals independently selected from -OH, oxo (=O), -CHO, -SH, $-NO_2$, -CN, -F, -Cl, -Br, $(C_1-C_4)$-alkanoyl, $(C_1-C_4)$-alkoxycarbonyl, $(C_1-C_4)$-alkanoyloxy, $(C_1-C_4)$-alkylsulphinyl, $(C_1-C_4)$-alkylsulphenyl, $(C_1-C_4)$-alkylsulphonyl, $(C_1-C_4)$-alkyloxy-$SO_2$-, $(C_1-C_4)$-alkyl-$SO_2O$-, -NR2R3, -CONR2R3, $(C_1-C_4)$-alkyl optionally substituted by one or several -OH or -F, and $(C_1-C_4)$-alkoxyl optionally substituted by one or several -OH or -F;

a.d) a radical from a five- or six-membered heterocycle containing from one to three heteroatoms selected from O, S and N, this heterocycle being optionally substituted by one or several radicals independently selected from -OH, oxo (=O), -CHO, -SH, $-NO_2$, -CN, -F, -Cl, -Br, $(C_1-C_4)$-alkanoyl, $(C_1-C_4)$-alkoxycarbonyl, $(C_1-C_4)$-alkanoyloxy, $(C_1-C_4)$-alkylsulphinyl, $(C_1-C_4)$-alkylsulphenyl, $(C_1-C_4)$-alkylsulphonyl, $(C_1-C_4)$-alkyloxy-$SO_2$-, $(C_1-C_4)$-alkyl-$SO_2O$-, -NR2R3, -CONR2R3, $(C_1-C_4)$-alkyl optionally substituted by one or several -OH or -F, and $(C_1-C_4)$-alkoxyl optionally substituted by one or several -OH or -F;

a.e) phenyl or phenyl optionally substituted by one or several radicals independently selected from -OH, -CHO, -SH, $-NO_2$, -CN, -F, -Cl, -Br, $(C_1-C_4)$-alkanoyl, $(C_1-C_4)$-alkoxycarbonyl, $(C_1-C_4)$-alkanoyloxy, $(C_1-C_4)$-alkylsulphinyl, $(C_1-C_4)$-alkylsulphenyl, $(C_1-C_4)$-alkylsulphonyl, $(C_1-C_4)$-alkyloxy-$SO_2$-, $(C_1-C_4)$-alkyl-$SO_2O$-, -NR2R3, -CONR2R3, $(C_1-C_4)$-alkyl optionally substituted by one or several -OH or -F, and

($C_1$-$C_4$)-alkoxyl optionally substituted by one or several -OH or -F; and

a.f) a radical from a bicyclic system consisting of a benzene fused with a five- or six-membered ring optionally containing from one to three heteroatoms selected from O, S and N, being this bicyclic system optionally substituted by one or several radicals independently selected from -OH, oxo (=O), -CHO, -SH, $-NO_2$, -CN, -F, -Cl, -Br, ($C_1$-$C_4$)-alkanoyl, ($C_1$-$C_4$)-alkoxycarbonyl, ($C_1$-$C_4$)-alkanoyloxy, ($C_1$-$C_4$)-alkylsulphinyl, ($C_1$-$C_4$)-alkylsulphenyl, ($C_1$-$C_4$)-alkylsulphonyl, ($C_1$-$C_4$)-alkyloxy-$SO_2$-, ($C_1$-$C_4$)-alkyl-$SO_2O$-, -NR2R3, -CONR2R3, ($C_1$-$C_4$)-alkyl optionally substituted by one or several -OH or -F, and ($C_1$-$C_4$)-alkoxyl optionally substituted by one or several -OH or -F;

b) -($CH_2$)$_s$-X-P-I-J-T wherein

s is 2 or 3;

-X- is selected from the group consisting of -O-, -S-, -SO-, $-SO_2$- and -NR4-, being R4 a radical selected from the group:

b.a) -H;

b.b) ($C_1$-$C_{10}$)-alkyl;

b.c) cycloalkyl, cycloalkyl-CO-, cycloalkyl-($C_1$-$C_3$)-alkyl and cycloalkyl-($C_1$-$C_3$)-alkanoyl, wherein the cycloalkyl is a five- or six-membered ring optionally substituted by one or several radicals selected from -OH, oxo (=O), -CHO, -SH, $-NO_2$, -CN, -F, -Cl, -Br, ($C_1$-$C_4$)-alkanoyl, ($C_1$-$C_4$)-alkoxycarbonyl, ($C_1$-$C_4$)-alkanoyloxy, ($C_1$-$C_4$)-alkylsulphinyl, ($C_1$-$C_4$)-alkylsulphenyl, ($C_1$-$C_4$)-alkylsulphonyl, ($C_1$-$C_4$)-alkyloxy-$SO_2$-, ($C_1$-$C_4$)-alkyl-$SO_2O$-, -NR2R3, -CONR2R3, ($C_1$-$C_4$)-alkyl optionally substituted by one or several -OH or -F, and -($C_1$-$C_4$)-alkoxyl optionally substituted by one or several OH

or F;

b.d) phenyl, phenyl-CO-, phenyl-($C_1$-$C_3$)-alkyl and phenyl-($C_1$-$C_3$)-alkanoyl, being this aromatic ring optionally substituted by one or several radicals selected from -OH, -CHO, -SH, -$NO_2$, -CN, -F, -Cl, -Br, ($C_1$-$C_4$)-alkanoyl, ($C_1$-$C_4$)-alkoxycarbonyl, ($C_1$-$C_4$)-alkanoyloxy, ($C_1$-$C_4$)-alkylsulphinyl, ($C_1$-$C_4$)-alkylsulphenyl, ($C_1$-$C_4$)-alkylsulphonyl, ($C_1$-$C_4$)-alkyloxy-$SO_2$-, ($C_1$-$C_4$)-alkyl-$SO_2O$-, -NR2R3, -CONR2R3, ($C_1$-$C_4$)-alkyl optionally substituted by one or several -OH or -F, and ($C_1$-$C_4$)-alkoxyl optionally substituted by one or several -OH or -F; and

b.e) a heterocycle, heterocycle-CO, heterocycle-($C_1$-$C_3$)-alkyl and heterocycle-($C_1$-$C_3$)-alkanoyl, wherein the heterocycle is a five- or six-membered ring containing from one to three heteroatoms selected from O, S and N, being this heterocycle optionally substituted by one or several radicals selected from -OH, oxo (=O), -CHO, -SH, -$NO_2$, -CN, -F, -Cl, -Br, ($C_1$-$C_4$)-alkanoyl, ($C_1$-$C_4$)-alkoxycarbonyl, ($C_1$-$C_4$)-alkanoyloxy, ($C_1$-$C_4$)-alkylsulphinyl, ($C_1$-$C_4$)-alkylsulphenyl, ($C_1$-$C_4$)-alkylsulphonyl, ($C_1$-$C_4$)-alkyloxy-$SO_2$-, ($C_1$-$C_4$)-alkyl-$SO_2O$-, -NR2R3, -CONR2R3, ($C_1$-$C_4$)-alkyl optionally substituted by one or several -OH or -F, and ($C_1$-$C_4$)-alkoxyl optionally substituted by one or several -OH or -F;

-P- is a bond or a -$(CH_2)_{1-4}$- biradical;

-I- is as defined above;

-J- is as defined above; and

-T is a radical as defined above;

c) -$(CH_2)_u$-CO-NR5-P-I-J-T wherein

u is 1 or 2;

-R5 is a radical selected from the group:

c.a) -H;

c.b) ($C_1$-$C_{10}$)-alkyl;

c.c) cycloalkyl and cycloalkyl-($C_1$-$C_3$)-alkyl, wherein the cycloalkyl is a five- or six-membered ring optionally substituted by one or several radicals selected from -OH, oxo (=O), -CHO, -SH, -$NO_2$, -CN, -F, -Cl, -Br, ($C_1$-$C_4$)-alkanoyl, ($C_1$-$C_4$)-alkoxycarbonyl, ($C_1$-$C_4$)-alkanoyloxy, ($C_1$-$C_4$)-alkylsulphinyl, ($C_1$-$C_4$)-alkylsulphenyl, ($C_1$-$C_4$)-alkylsulphonyl, ($C_1$-$C_4$)-alkyloxy-$SO_2$-, ($C_1$-$C_4$)-alkyl-$SO_2O$-, -NR2R3, -CONR2R3, ($C_1$-$C_4$)-alkyl optionally substituted by one or several -OH or -F, and ($C_1$-$C_4$)-alkoxyl optionally substituted by one or several -OH or -F;

c.d) phenyl and phenyl-($C_1$-$C_3$)-alkyl, being this aromatic ring optionally substituted by one or several radicals selected from -OH, -CHO, -SH, -$NO_2$, -CN, -F, -Cl, -Br, ($C_1$-$C_4$)-alkanoyl, ($C_1$-$C_4$)-alkoxycarbonyl, ($C_1$-$C_4$)-alkanoyloxy, ($C_1$-$C_4$)-alkylsulphinyl, ($C_1$-$C_4$)-alkylsulphenyl, ($C_1$-$C_4$)-alkylsulphonyl, ($C_1$-$C_4$)-alkyloxy-$SO_2$-, ($C_1$-$C_4$)-alkyl-$SO_2O$-, -NR2R3, -CONR2R3, ($C_1$-$C_4$)-alkyl optionally substituted by one or several -OH or -F, and ($C_1$-$C_4$)-alkoxyl optionally substituted by one or several -OH or -F; and

c.e) a heterocycle and heterocycle-($C_1$-$C_3$)-alkyl, wherein the heterocycle is a five- or six-membered ring containing from one to three heteroatoms selected from O, S and N, being this heterocyclo optionally substituted by one or several radicals selected from -OH, oxo (=O), -CHO, -SH, -$NO_2$, -CN, -F, -Cl, -Br, ($C_1$-$C_4$)-alkanoyl, ($C_1$-$C_4$)-alkoxycarbonyl, ($C_1$-$C_4$)-alkanoyloxy, ($C_1$-$C_4$)-alkylsulphinyl, ($C_1$-$C_4$)-alkylsulphenyl,

($C_1$-$C_4$)-alkylsulphonyl, ($C_1$-$C_4$)-alkyloxy-$SO_2$-, ($C_1$-$C_4$)-alkyl-$SO_2O$-, -NR2R3, -CONR2R3, ($C_1$-$C_4$)-alkyl optionally substituted by one or severalseveral -OH or -F, and ($C_1$-$C_4$)-alkoxyl optionally substituted by one or several -OH or -F;

-P- is as defined above;

-I- is as defined above;

-J- is as defined above; and

-T is as defined above;

d) -$(CH_2)_s$-NR6R7, wherein s is as defined above, and R6 and R7 together with the N are joined forming a five-, six-, or seven-membered cycle optionally containing from one to three additional heteroatoms selected from O, S and N, and that may be fused or substituted by one or two five- or six-membered cycles optionally containing one or several heteroatoms selected from the group composed of O, S and N, all the cycles being optionally substituted by one or several radicals independently selected from -OH, oxo (=O), -CHO, -SH, -$NO_2$, -CN, -F, -Cl, -Br, ($C_1$-$C_4$)-alkanoyl, ($C_1$-$C_4$)-alkoxycarbonyl, ($C_1$-$C_4$)-alkanoyloxy, ($C_1$-$C_4$)-alkylsulphinyl, ($C_1$-$C_4$)-alkylsulphenyl, ($C_1$-$C_4$)-alkylsulphonyl, ($C_1$-$C_4$)-alkyloxy-$SO_2$-, ($C_1$-$C_4$)-alkyl-$SO_2O$-, -NR2R3, -CONR2R3, ($C_1$-$C_4$)-alkyl optionally substituted by one or several -OH or -F, and ($C_1$-$C_4$)-alkoxyl optionally substituted by one or several -OH or -F; and

e) -$(CH_2)_u$-CO-NR6R7 wherein u is as defined above, and R6 and R7 are as defined above;

with the proviso that compound of formula (I) is neither of 2-(4-benzyloxybenzoylamino)-3-phenylpropionic acid, 2-[4-(4-methoxybenzyloxy) benzoylamino]-3-phenylpropionic acid, 2-[4-(4-bromobenzyloxy)benzoylamino]-3-phenylpropionic acid, cyclopentyl-[4-(2-methylquinolin-4-ylmethoxy) benzoylamino] acetic acid methyl ester, [4-(2-

methylquinolin-4-ylmethoxy) benzoylamino] (tetrahydropyran-4-yl) acetic acid methyl ester or 2-(4-benzyloxybenzoylamino)-3-biphenyl-4-ylpropionic acid or 2-(4-benzyloxybenzoylamino)-3-(4'-trifluoromethoxybiphenyl-4-yl) propionic acid.

2. (Original) The compound according to claim 1, wherein W is -NH-CH(E)-.

3. (Original) The compound according to claim 2, wherein -Z is a radical of the -Q-I-J-T type.

4. (Original) The compound according to claim 2, wherein -Z is a radical of the $-(CH_2)_s$-X-P-I-J-T type.

5. (Original) The compound according to claim 4, wherein -X- is -O-.

6. (Original) The compound according to claim 4, wherein s is 2 and -X- is -NR4-.

7. (Original) The compound of claim 1, wherein W is $-N(E)-CH_2-CH_2-$.

8. (Original) The compound according to claim 7, wherein -Z is a radical of the -Q-I-J-T type.

9. (Original) The compound according to claim 7, wherein -Z is a radical of the $-(CH_2)_s$-X-P-I-J-T type.

10. (Original) The compound according to claim 9, wherein -X- is -O-.

11. (Original) The compound according to claim 9, wherein s is 2 and -X- is -NR4-.

12. (Original) The compound according to claim 1, wherein -A is an -OR1 type radical.

13. (Original) The compound according to claim 1 selected from the group consisting of:

(2*S*)-3-(4-benzyloxyphenyl)-2-[4-(4-butoxybenzyloxy)benzoylamino]propionic acid methyl ester;

(2*S*)-3-(4-benzyloxyphenyl)-2-[4-(3-bromobenzyloxy)benzoylamino]propionic acid methyl ester;

(2*S*)-3-(4-benzyloxyphenyl)-2-[4-(2-chlorobenzyloxy)benzoylamino]propionic acid methyl ester;

(2*S*)-3-(4-benzyloxyphenyl)-2-[4-(2-fluorobenzyloxy)benzoylamino]propionic acid methyl ester;

(2*S*)-3-(4-benzyloxyphenyl)-2-[4-(3-methylbenzyloxy)benzoylamino]propionic acid methyl ester;

(2*S*)-3-(4-benzyloxyphenyl)-2-[4-(3-trifluoromethylbenzyloxy)benzoylamino]propionic acid methyl ester;

(2*S*)-3-(4-benzyloxyphenyl)-2-[4-(2-methoxybenzyloxy)benzoylamino]propionic acid methyl ester;

(2*S*)-3-(4-benzyloxyphenyl)-2-[4-(2-methylbenzyloxy)benzoylamino]propionic acid methyl ester;

(2*S*)-3-(4-benzyloxyphenyl)-2-[4-(2-trifluoromethylbenzyloxy)benzoylamino]propionic acid methyl ester;

(2*S*)-3-(4-benzyloxyphenyl)-2-[4-(2-*o*-tolylethoxy)benzoylamino]propionic acid methyl ester;

(2*S*)-3-(4-benzyloxyphenyl)-2-{4-[3-(4-propoxyphenoxy)propoxy]benzoylamino}propionic acid methyl ester;

(2*S*)-3-(4-benzyloxyphenyl)-2-[4-(3-methoxybenzyloxy)benzoylamino]propionic acid methyl ester;

(2*S*)-3-(4-benzyloxyphenyl)-2-[4-(2-ethoxybenzyloxy)benzoylamino]propionic acid methyl ester;

(2*S*)-3-(4-benzyloxyphenyl)-2-[4-(4-butylbenzyloxy)benzoylamino]propionic acid methyl ester;

(2*S*)-2-[4-(4-butylbenzyloxy)benzoylamino]-3-cyclohexylpropionic acid methyl ester;

(2*S*)-2-{4-[2-(3-methylquinoxalin-2yloxy)ethoxy]benzoylamino}-3-phenylpropionic

acid methyl ester;
(2*S*)-3-(4-benzyloxyphenyl)-2-[4-(2-pyridin-2-ylethoxy)benzoylamino]propionic acid methyl ester;
(2*S*)-3-(4-benzyloxyphenyl)-2-{4-[2-(3-methylquinoxalin-2-yloxy)ethoxy]benzoylamino}propionic acid methyl ester;
(2*S*)-3-(4-benzyloxyphenyl)-2-{4-[2-(pyridin-2-yloxy)ethoxy]benzoylamino}propionic acid methyl ester;
(2*S*)-3-(4-benzyloxyphenyl)-2-{4-[2-(quinolin-8-yloxy)ethoxy]benzoylamino}propionic acid methyl ester;
(2*S*)-3-(4-benzyloxyphenyl)-2-{4-[2-(quinolin-7-yloxy)ethoxy]benzoylamino}propionic acid methyl ester;
(2*S*)-3-(4-benzyloxyphenyl)-2-{4-[2-(quinolin-2-yloxy)ethoxy]benzoylamino}propionic acid methyl ester;
(2*S*)-3-(4-benzyloxyphenyl)-2-{4-[3-(3-methylquinoxalin-2-yloxy)propoxy]benzoylamino}propionic acid methyl ester;
(2*S*)-3-(4-bromophenyl)-2-{4-[2-(3-methylquinoxalin-2-yloxy)ethoxy]benzoylamino}propionic acid methyl ester;
(2*S*)-3-(4-fluorophenyl)-2-{4-[2-(3-methylquinoxalin-2-yloxy)ethoxy]benzoylamino}propionic acid methyl ester;
(2*S*)-3-(4-benzyloxyphenyl)-2-{4-[2-(3-methylquinoxalin-2-yloxy)ethoxy]benzoylamino}propionic acid ethyl ester;
(2*S*)-3-(4-benzyloxyphenyl)-2-{4-[2-(3-methylquinoxalin-2-yloxy)ethoxy]benzoylamino}propionic acid isopropyl ester;
(2*S*)-3-(4-benzyloxyphenyl)-2-{4-[2-(3-methylquinoxalin-2-yloxy)ethoxy]benzoylamino}propionic acid propyl ester;
(2*S*)-2-(4-benzyloxybenzoylamino)-3-(4-benzyloxyphenyl)propionic acid;
(2*S*)-2-[4-(3-benzyloxybenzyloxy)benzoylamino]-3-(4-benzyloxyphenyl)propionic acid;
3-{(3-benzyloxybenzyl)-[4-(2-dibenzylaminoethoxy)benzoyl]amino}propionic acid;
3-((3-benzyloxybenzyl)-{3-[2-(3-methylquinoxalin-2-yloxy)ethoxy]benzoyl}amino)propionic acid;
3-{(3-benzyloxybenzyl)-[4-(3-benzyloxybenzyloxy)benzoyl]amino}propionic acid;

2-[4-(4-benzyloxybenzyloxy)benzoylamino]-3-(4-benzyloxyphenyl)propionic acid;
(2*S*)-2-[3-(4-benzyloxybenzyloxy)benzoylamino]-3-(4-benzyloxyphenyl)propionic acid;
3-(4-benzyloxyphenyl)-2-[3-(biphenyl-4-ylmethoxy)benzoylamino]propionic acid;
2-[4-(3-benzyloxybenzyloxy)benzoylamino]-3-(4-bromophenyl)propionic acid;
3-(4-benzyloxyphenyl)-2-[4-(4-butylbenzyloxy)benzoylamino]propionic acid;
2-[4-(4-butylbenzyloxy)benzoylamino]-3-cyclohexylpropionic acid;
{(3-benzyloxybenzyl)-[4-(4-butylbenzyloxy)benzoyl]amino}acetic acid;
3-{(3-benzyloxybenzyl)-[4-(4-butylbenzyloxy)benzoyl]amino}propionic acid;
3-(4-benzyloxyphenyl)-2-[4-(2-bromobenzyloxy)benzoylamino]propionic acid;
3-(4-benzyloxyphenyl)-2-[4-(2-chlorobenzyloxy)benzoylamino]propionic acid;
3-(4-benzyloxyphenyl)-2-[4-(2-methylbenzyloxy)benzoylamino]propionic acid;
3-(4-benzyloxyphenyl)-2-[4-(3-trifluoromethylbenzyloxy)benzoylamino]propionic acid; and
3-(4-benzyloxyphenyl)-2-[4-(2-trifluoromethylbenzyloxy)benzoylamino]propionic acid.

14. (Currently amended) A pharmaceutical composition comprising, as an active ingredient, a therapeutically effective amount of the compound according to ~~any one of the~~ claims ~~1 to 13~~ together with appropriate amounts of pharmaceutically acceptable excipients.

15-29. (Canceled)

30. (Original) A method for the prophylactic and/or curative treatment of a condition mediated by PPARγ in an animal including a human, comprising administering a therapeutically effective amount of a compound as defined in claim 1 together with an appropriate amount of pharmaceutically acceptable excipients.

31. (Original) A method for the prophylactic and/or curative treatment of a condition mediated by both PPARγ and PPARδ in an animal including a human, comprising administering a therapeutically effective amount of a compound as

defined in claim 1 together with an appropriate amount of pharmaceutically acceptable excipients.

32. (Currently amended) The method according to ~~any one of~~ claim~~s~~ 30 ~~or 31~~, wherein the administration is carried out orally, parenterally or topically.

33. (Currently amended) A method for the prophylactic and/or curative treatment of an animal including a human, suffering from a condition associated with metabolic diseases, comprising administering a ~~therapeutically~~ therapeutically effective amount of a compound as defined in claim 1 together with an appropriate amount of pharmaceutically acceptable excipients.

34. (Currently amended) A method for the prophylactic and/or curative treatment of an animal including a human, suffering from a cardiovascular disease associated with metabolic syndrome, comprising administering a ~~therapeutically~~ therapeutically effective amount of a compound as defined in claim 1 together with an appropriate amount of pharmaceutically acceptable excipients.

35. (Currently amended) A method for the prophylactic and/or curative treatment of an animal, including a human, suffering from inflammation or an inflammatory process in general, comprising administering a ~~therapeutically~~ therapeutically effective amount of a compound as defined in claim 1 together with an appropriate amount of pharmaceutically acceptable excipients.

36. (Currently amended) A method for the prophylactic and/or curative treatment of an animal, including a human, suffering from bone diseases comprising administering a ~~therapeutically~~ therapeutically effective amount of a compound as defined in claim 1 together with an appropriate amount of pharmaceutically acceptable excipients.

37. (Currently amended) A method for the prophylactic and/or curative treatment of an animal, including a human, suffering from cancer, comprising administering a

~~therapeutically~~ therapeutically effective amount of a compound as defined in claim 1 together with an appropriate amount of pharmaceutically acceptable excipients.

38. (Currently amended) A method for the prophylactic and/or curative treatment of an animal, including a human, suffering from skin wound healing or cutaneous disorders associated with an anomalous differentiation of epidermic cells, particularly the formation of keloids, comprising administering a ~~therapeutically~~ therapeutically effective amount of a compound as defined in claim 1 together with an appropriate amount of pharmaceutically acceptable excipients.

39. (New) The method of claim 33, wherein the metabolic disease is non-insulin-dependent diabetes mellitus (NIDDM).

40. (New) The method of claim 33, wherein the metabolic disease is obesity.

41. (New) The method of claim 33, wherein the metabolic disease is selected from hypercholesterolaemia and other lipid-mediated pathologies.

42. (New) The method of claim 35, wherein the inflammatory process is selected from rheumatoid arthritis and atherosclerosis.

43. (New) The method of claim 35, wherein the inflammatory process is selected from psoriasis and intestinal inflammatory disease.

44. (New) The method according to claim 31, wherein the administration is carried out orally, parenterally or topically.